Chinese sci-tech innovation information provider PatSnap, on Wednesday, launched a database focusing on tracking global new drug updates.
It will also provide information services for Research and Development (R&D) decision-makers of pharmaceutical enterprises, industrial researchers and investors, reported the Xinhua-run China Securities Journal.
The database, named PharmSnap, currently covers more than 39,000 new drugs around the world, 4,600 drug targets, 270,000 drug research institutions, 10 million drug-related patents, 21 million pieces of medical literature, 410,000 pieces of clinical data and rich industry news.
The founder and CEO of PatSnap, Zhang Jihui, said that the global new drug database offers all the data required for pharmaceutical R&D project development to users free of charge, also estimated that the free database would provide services to more than 5 million professionals around the world.
Based on PatSnap’s data amassing in the field of intellectual property and artificial intelligence technologies such as machine learning, computer vision and natural language processing, PharmSnap mainly serves four application scenarios, namely investigation into pharmaceutical project development, R&D decision-making support, business expansion and cooperation, and timely tracking of competing products.
The director of biomedical data of PatSnap, Pei Lidong, said that PatSnap came as a relatively mature product after nearly two years of preparation and full verification of the beta version in partnership with the strategic departments and business departments of many overseas pharmaceutical giants.